We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
Read MoreHide Full Article
Agenus Inc. (AGEN - Free Report) announced that it has out-licensed its proprietary bispecific antibody program, AGEN1777, and a second undisclosed target, to Bristol-Myers Squibb Company (BMY - Free Report) .
Shares of Agenus were up 20.5% on Tuesday following the announcement. In fact, the stock has rallied 23.6% so far this year against the industry’s decline of 5.6%.
Per the definitive license agreement, Agenus will receive an upfront payment of $200 million from Bristol-Myers. The company is eligible to receive up to $1.36 billion in development/commercial and regulatory milestone payments, along with tiered double-digit royalties on net product sales, if approved. Meanwhile, Bristol-Myers will be responsible for the development and subsequent commercialization of AGEN1777 across the world.
The deal is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Per the deal, Agenus will have the option to conduct clinical and combination studies with certain of its pipeline assets, and upon potential commercialization, to co-promote AGEN1777 in the United States. Notably, AGEN1777 is a first-in-class bispecific anti-TIGIT antibody which is currently in preclinical studies designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
Agenus plans to file an investigational new drug application for AGEN1777 in the second quarter of 2021 to the FDA. A phase I study on the same is expected to begin in the third quarter of 2021.
Meanwhile, Bristol-Myers is looking to advance the development of AGEN1777 for immuno-oncology indications, including non-small cell lung cancer.
We remind investors that Agenus has submitted a biologics license application to the FDA for accelerated approval of its pipeline candidate, balstilimab, which is being developed for treating patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
Athenex’s loss per share estimates have narrowed 21.8% for 2021 and 23.2% for 2022 over the past 60 days.
Adaptive Biotechnologies’ loss per share estimates have narrowed 11.7% for 2021 and 2.3% for 2022 over the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
Agenus Inc. (AGEN - Free Report) announced that it has out-licensed its proprietary bispecific antibody program, AGEN1777, and a second undisclosed target, to Bristol-Myers Squibb Company (BMY - Free Report) .
Shares of Agenus were up 20.5% on Tuesday following the announcement. In fact, the stock has rallied 23.6% so far this year against the industry’s decline of 5.6%.
Per the definitive license agreement, Agenus will receive an upfront payment of $200 million from Bristol-Myers. The company is eligible to receive up to $1.36 billion in development/commercial and regulatory milestone payments, along with tiered double-digit royalties on net product sales, if approved. Meanwhile, Bristol-Myers will be responsible for the development and subsequent commercialization of AGEN1777 across the world.
The deal is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Per the deal, Agenus will have the option to conduct clinical and combination studies with certain of its pipeline assets, and upon potential commercialization, to co-promote AGEN1777 in the United States. Notably, AGEN1777 is a first-in-class bispecific anti-TIGIT antibody which is currently in preclinical studies designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
Agenus plans to file an investigational new drug application for AGEN1777 in the second quarter of 2021 to the FDA. A phase I study on the same is expected to begin in the third quarter of 2021.
Meanwhile, Bristol-Myers is looking to advance the development of AGEN1777 for immuno-oncology indications, including non-small cell lung cancer.
We remind investors that Agenus has submitted a biologics license application to the FDA for accelerated approval of its pipeline candidate, balstilimab, which is being developed for treating patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
Zacks Rank & Stocks to Consider
Agenus currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Athenex, Inc. and Adaptive Biotechnologies Corporation (ADPT - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Athenex’s loss per share estimates have narrowed 21.8% for 2021 and 23.2% for 2022 over the past 60 days.
Adaptive Biotechnologies’ loss per share estimates have narrowed 11.7% for 2021 and 2.3% for 2022 over the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>